Availability of antiretroviral therapy after clinical trials with HIV infected patients are ended.

Describes the dilemma faced by the South African ethics committee asked to approve the clinical trials of treatment for HIV infection after the end of the trial. Responsibility of a trial sponsor to a trial subject to responds to treatment; Concerns on the large number of people insufficiently educated to understand the implications of the clinical trials.